ZA9811234B - Oral pharmaceutical pulsed release dosage form - Google Patents

Oral pharmaceutical pulsed release dosage form

Info

Publication number
ZA9811234B
ZA9811234B ZA9811234A ZA9811234A ZA9811234B ZA 9811234 B ZA9811234 B ZA 9811234B ZA 9811234 A ZA9811234 A ZA 9811234A ZA 9811234 A ZA9811234 A ZA 9811234A ZA 9811234 B ZA9811234 B ZA 9811234B
Authority
ZA
South Africa
Prior art keywords
dosage form
release dosage
oral pharmaceutical
pulsed release
pulsed
Prior art date
Application number
ZA9811234A
Other languages
English (en)
Inventor
Per Johan Lundberg
Brita Sjoeblom
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Publication of ZA9811234B publication Critical patent/ZA9811234B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA9811234A 1997-12-22 1998-12-08 Oral pharmaceutical pulsed release dosage form ZA9811234B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9704870A SE9704870D0 (sv) 1997-12-22 1997-12-22 New pharmaceutical formulation I

Publications (1)

Publication Number Publication Date
ZA9811234B true ZA9811234B (en) 1999-06-22

Family

ID=20409572

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9811234A ZA9811234B (en) 1997-12-22 1998-12-08 Oral pharmaceutical pulsed release dosage form

Country Status (40)

Country Link
US (1) US6610323B1 (de)
EP (1) EP1043977B1 (de)
JP (1) JP4907765B2 (de)
KR (1) KR100616027B1 (de)
CN (1) CN1245155C (de)
AR (1) AR017202A1 (de)
AT (1) ATE252379T1 (de)
AU (1) AU759311B2 (de)
BG (1) BG65008B1 (de)
BR (1) BR9814389A (de)
CA (1) CA2315927C (de)
CZ (1) CZ299227B6 (de)
DE (1) DE69819205T2 (de)
DK (1) DK1043977T3 (de)
DZ (1) DZ2686A1 (de)
EE (1) EE04417B1 (de)
EG (1) EG23875A (de)
ES (1) ES2209240T3 (de)
HK (1) HK1034668A1 (de)
HR (1) HRP20000381B1 (de)
HU (1) HUP0200618A3 (de)
ID (1) ID27040A (de)
IL (1) IL136823A (de)
IS (1) IS2184B (de)
MA (1) MA26577A1 (de)
MY (1) MY130765A (de)
NO (1) NO20003219L (de)
NZ (1) NZ505135A (de)
PL (1) PL341565A1 (de)
PT (1) PT1043977E (de)
RU (1) RU2205028C2 (de)
SE (1) SE9704870D0 (de)
SK (1) SK284545B6 (de)
TN (1) TNSN98230A1 (de)
TR (1) TR200001982T2 (de)
TW (1) TWI240637B (de)
UA (1) UA69396C2 (de)
WO (1) WO1999032093A1 (de)
YU (1) YU36600A (de)
ZA (1) ZA9811234B (de)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945124A (en) 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
FR2774288B1 (fr) * 1998-01-30 2001-09-07 Ethypharm Sa Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques
DK1105105T3 (da) 1998-08-12 2006-07-17 Altana Pharma Ag Oral administrationsform til pyridin-2-ylmethylsulfinyl-1H-benzimidazoler
JP2000128779A (ja) * 1998-10-20 2000-05-09 Mitsui Chemicals Inc 薬物放出制御型製剤
FR2793688B1 (fr) 1999-05-21 2003-06-13 Ethypharm Lab Prod Ethiques Microgranules gastroproteges, procede d'obtention et preparations pharmaceutiques
GB9923045D0 (en) * 1999-09-29 1999-12-01 Novartis Ag New oral formulations
GB9923436D0 (en) * 1999-10-04 1999-12-08 American Home Prod Pharmaceutical compositions
CA2389235C (en) 1999-10-29 2007-07-17 Euro-Celtique, S.A. Controlled release hydrocodone formulations
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US7029701B2 (en) * 2000-09-11 2006-04-18 Andrx Pharmaceuticals, Llc Composition for the treatment and prevention of ischemic events
US7157095B2 (en) * 2000-10-13 2007-01-02 Advancis Pharmaceutical Corporation Multiple-delayed release antifungal product, use and formulation thereof
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
EP2283829A1 (de) 2000-10-30 2011-02-16 Euro-Celtique S.A. Hydrocodon-Formulierungen mit gesteuerter Freisetzung
JP2002234842A (ja) * 2001-02-09 2002-08-23 Kyowa Yakuhin Kogyo Kk 内服腸溶性製剤
US7316819B2 (en) * 2001-03-08 2008-01-08 Unigene Laboratories, Inc. Oral peptide pharmaceutical dosage form and method of production
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
US20050163846A1 (en) * 2001-11-21 2005-07-28 Eisai Co., Ltd. Preparation composition containing acid-unstable physiologically active compound, and process for producing same
MY148805A (en) * 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
ES2534713T3 (es) 2002-10-16 2015-04-27 Takeda Pharmaceutical Company Limited Preparaciones sólidas estables
WO2004039361A1 (en) * 2002-10-25 2004-05-13 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
EP1581196A4 (de) * 2002-12-23 2007-08-22 Celltech Americas Inc Säurelabile arzneimittelzusammensetzungen
JP2004231520A (ja) * 2003-01-28 2004-08-19 Nichiko Pharmaceutical Co Ltd 保存安定性及び溶出速度に優れた医薬組成物
US20040146558A1 (en) * 2003-01-28 2004-07-29 Kyowa Pharmaceutical Co., Ltd. Oral enteric-coated preparation
US8980322B2 (en) 2003-03-17 2015-03-17 Takeda Pharmaceutical Company Limited Controlled release composition
JP4933033B2 (ja) * 2003-03-17 2012-05-16 武田薬品工業株式会社 放出制御組成物
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
AU2004258944B2 (en) 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
AU2004258949B2 (en) 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
AU2004258953B2 (en) 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
AU2004264939A1 (en) 2003-08-11 2005-02-24 Middlebrook Pharmaceuticals, Inc. Robust pellet
CA2535398C (en) 2003-08-12 2013-11-12 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
CA2535780A1 (en) * 2003-08-29 2005-03-17 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
EP1667665B1 (de) * 2003-09-03 2009-01-07 Pharmaton S.A. Kapseln enthaltend wirkstoffpellets mit unterschiedlichen freisetzungsprofilen
AU2004273830B2 (en) 2003-09-15 2011-03-24 Shionogi, Inc. Antibiotic product, use and formulation thereof
AU2004275835B2 (en) * 2003-09-26 2011-06-23 Alza Corporation Controlled release formulations exhibiting an ascending rate of release
US20050089570A1 (en) * 2003-09-26 2005-04-28 Evangeline Cruz Oros push-stick for controlled delivery of active agents
AU2004314693B2 (en) 2003-09-26 2011-04-07 Alza Corporation Drug coating providing high drug loading and methods for providing the same
EP1680094A1 (de) * 2003-09-26 2006-07-19 Alza Corporation Formulierungen von opioid- und nichtopioid-analgetika mit kontrollierter freisetzung
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
JP2005272347A (ja) * 2004-03-24 2005-10-06 Ohara Yakuhin Kogyo Kk 固形製剤の製造方法
JPWO2005092336A1 (ja) * 2004-03-26 2008-02-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 溶出制御製剤とその製造方法
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
AU2011205024B2 (en) * 2004-06-16 2012-09-06 Takeda Pharmaceutical Company Limited Multiple PPI dosage form
JP5563735B2 (ja) * 2004-06-16 2014-07-30 タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド Ｐｐｉ多回剤形
EP1771158A4 (de) 2004-07-02 2008-03-12 Advancis Pharmaceutical Corp Tablette für pulsierte abgabe
US8541026B2 (en) * 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
AR052225A1 (es) * 2004-11-04 2007-03-07 Astrazeneca Ab Formulaciones de tabletas de liberacion modificada par inhibidores de la bomba de protones
AR051654A1 (es) * 2004-11-04 2007-01-31 Astrazeneca Ab Nuevas formulaciones de pellets de liberacion modificada para inhibidores de la bomba de protones
US7226454B2 (en) * 2004-12-07 2007-06-05 Arizant Healthcare Inc. Warming device with varied permeability
WO2006111853A2 (en) * 2005-04-18 2006-10-26 Aurobindo Pharma Limited Stable solid dosage forms of acid labile drug
US7981908B2 (en) 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
US7803817B2 (en) 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
EP1754471A1 (de) * 2005-08-18 2007-02-21 ORAMON-Arzneimittel GmbH & Co. KG Verwendung einer quellbaren Zwischenschicht zur Steuerung des Freisetzungsprofils einer festen Arzneimittelformulierung zur peroralen Anwendung und diese enthaltende Arzneimittelformulierung
EP1930030A1 (de) * 2005-09-29 2008-06-11 Eisai R&D Management Co., Ltd. Puls-präparat mit verbesserten zerfallseigenschaften in vivo
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
RU2467740C2 (ru) * 2005-12-28 2012-11-27 Такеда Фармасьютикал Компани Лимитед Твердое лекарственное средство с контролируемым высвобождением
CA2634969A1 (en) * 2005-12-28 2007-07-05 Takeda Pharmaceutical Company Limited Controlled release solid preparation
US9532945B2 (en) * 2006-04-04 2017-01-03 Kg Acquisition Llc Oral dosage forms including an antiplatelet agent and an enterically coated acid inhibitor
PL2007362T3 (pl) 2006-04-04 2019-02-28 Kg Acquisition Llc Doustne postacie leku obejmujące czynnik przeciwpłytkowy i inhibitor kwasu
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
JP2009538901A (ja) * 2006-06-01 2009-11-12 デクセル ファーマ テクノロジーズ エルティーディー． 複式ユニット製薬的製剤
WO2008012621A2 (en) 2006-07-25 2008-01-31 Vecta, Ltd. Compositions and meth0ds for inhibiting gastric acide secretion using derivatives of small dicarboxylic acids in combination with ppi
WO2008062320A2 (en) * 2006-10-06 2008-05-29 Eisai R&D Management Co., Ltd Extended release formulations of a proton pump inhibitor
ITMI20062290A1 (it) * 2006-11-28 2008-05-29 Monteres S R L Compresse stabili allo stoccaggio a base di derivati del benzimidazolo rivestite con film gastro-resistente
EP1970056A1 (de) * 2007-03-15 2008-09-17 Polichem S.A. Zeitspezifische Dosierformen mit verzögerter/pulsatiler Freisetzung
GB2461822B (en) * 2007-03-20 2011-09-21 Isp Investments Inc Meltable binder for melt granulation and/or pelletization
WO2009017716A2 (en) * 2007-07-27 2009-02-05 Depomed, Inc. Pulsatile gastric retentive dosage forms
CA2702356C (en) * 2007-10-12 2014-02-11 Takeda Pharmaceuticals North America, Inc. Pharmaceutical formulation comprising a proton pump inhibitor for the treatment of gastrointestinal conditions independent of food intake
AU2009230676A1 (en) * 2008-03-24 2009-10-01 Lupin Limited Delayed release compositions of duloxetine
AU2009290712A1 (en) 2008-09-09 2010-03-18 Astrazeneca Ab Method for delivering a pharmaceutical composition to patient in need thereof
JP2012531430A (ja) * 2009-06-25 2012-12-10 ポーゼン インコーポレイテッド アスピリン療法を必要とする患者を治療するための方法
CA2764963C (en) 2009-06-25 2016-11-01 Astrazeneca Ab Method for treating a patient at risk for developing an nsaid-associated ulcer
GB201003731D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Immediate/delayed drug delivery
GB201003766D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Pulsatile drug release
GB201003734D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Delayed prolonged drug delivery
WO2012051495A2 (en) 2010-10-15 2012-04-19 The Research Foundation Of State University Of New York Compositions and methods for enhancing the biological response to chemical agents and physical stimuli
UA115139C2 (uk) 2011-12-28 2017-09-25 Поузен Інк. Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
EP3421032A4 (de) * 2016-02-23 2019-10-23 Nipro Corporation Teilchen einer pharmazeutischen zusammensetzung , oral zerfallende zubereitung damit und verfahren zur herstellung von teilchen einer pharmazeutischen zusammensetzung
US10736855B2 (en) 2016-02-25 2020-08-11 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
KR101884230B1 (ko) * 2016-02-29 2018-08-01 주식회사 유영제약 에소메프라졸을 포함하는 제제
CN105796531A (zh) * 2016-04-13 2016-07-27 中国药科大学 一种右旋兰索拉唑择时脉冲控释微丸制剂及其制备方法
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
JP6915258B2 (ja) * 2016-10-21 2021-08-04 ニプロ株式会社 医薬組成物粒子とそれを含む口腔内崩壊製剤、医薬組成物粒子の製造方法
CN109125282B (zh) * 2018-09-05 2020-07-14 珠海润都制药股份有限公司 一种奥美拉唑肠溶胶囊及其制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8301182D0 (sv) 1983-03-04 1983-03-04 Haessle Ab Novel compounds
IL75400A (en) 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
AU4640985A (en) 1984-08-31 1986-03-06 Nippon Chemiphar Co. Ltd. Benzimidazole derivatives
GB8518301D0 (en) * 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
US5330982A (en) 1986-12-17 1994-07-19 Glaxo Group Limited Pharmaceutical composition containing a 5-HT receptor antagonist and an H+ K+ Atpase inhibitor and a method of treating gastrointestingal disorders therewith
GB8903564D0 (en) 1989-02-16 1989-04-05 Rashid Abdul Drug dispensing device
EP0458887A1 (de) 1989-02-16 1991-12-04 Btg International Limited Wirkstoffabgabevorrichtung
US5229131A (en) 1990-02-05 1993-07-20 University Of Michigan Pulsatile drug delivery system
JPH04273816A (ja) * 1991-02-26 1992-09-30 Tanabe Seiyaku Co Ltd パルス放出型有核錠
SE9301830D0 (sv) 1993-05-28 1993-05-28 Ab Astra New compounds
JPH072650A (ja) 1993-06-18 1995-01-06 Tanabe Seiyaku Co Ltd 放出部位制御型製剤
SE9302395D0 (sv) 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
SE9302396D0 (sv) 1993-07-09 1993-07-09 Ab Astra A novel compound form
HUT78132A (hu) * 1994-07-08 2000-06-28 Astra Aktiebolag Omeprazol magnéziumsóját tartalmazó új orális gyógyszerforma
SE9402431D0 (sv) 1994-07-08 1994-07-08 Astra Ab New tablet formulation
DE29522419U1 (de) * 1994-07-08 2003-07-03 AstraZeneca AB, Södertälje Tablettierte Mehrfacheinheits-Dosisform
JPH08157392A (ja) * 1994-12-01 1996-06-18 Kanegafuchi Chem Ind Co Ltd 放出制御型製剤
SE9500422D0 (sv) 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
US5567441A (en) 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
US6132768A (en) 1995-07-05 2000-10-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for reversible proton pump inhibitors
US5945124A (en) 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
SE9600071D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
WO1997047285A1 (en) * 1996-06-10 1997-12-18 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
SE9602442D0 (sv) 1996-06-20 1996-06-20 Astra Ab Administration of pharmaceuticals

Also Published As

Publication number Publication date
WO1999032093A1 (en) 1999-07-01
HUP0200618A2 (hu) 2002-07-29
SK284545B6 (sk) 2005-06-02
JP4907765B2 (ja) 2012-04-04
CZ299227B6 (cs) 2008-05-21
IL136823A0 (en) 2001-06-14
ATE252379T1 (de) 2003-11-15
SK8082000A3 (en) 2001-02-12
DK1043977T3 (da) 2004-02-09
CN1245155C (zh) 2006-03-15
ES2209240T3 (es) 2004-06-16
CA2315927C (en) 2008-03-18
YU36600A (sh) 2003-01-31
EG23875A (en) 2007-11-27
TNSN98230A1 (fr) 2005-03-15
TR200001982T2 (tr) 2001-02-21
RU2205028C2 (ru) 2003-05-27
ID27040A (id) 2001-02-22
MY130765A (en) 2007-07-31
CZ20002313A3 (cs) 2000-11-15
IS5541A (is) 2000-06-19
HK1034668A1 (en) 2001-11-02
SE9704870D0 (sv) 1997-12-22
KR20010033427A (ko) 2001-04-25
KR100616027B1 (ko) 2006-08-28
BG65008B1 (bg) 2006-12-29
DE69819205T2 (de) 2004-08-26
AU1991399A (en) 1999-07-12
HRP20000381B1 (en) 2004-12-31
DZ2686A1 (fr) 2003-03-29
UA69396C2 (uk) 2004-09-15
NZ505135A (en) 2002-06-28
AR017202A1 (es) 2001-08-22
DE69819205D1 (de) 2003-11-27
HRP20000381A2 (en) 2000-12-31
BG104619A (en) 2001-04-30
US6610323B1 (en) 2003-08-26
JP2001526213A (ja) 2001-12-18
IS2184B (is) 2006-12-15
EE04417B1 (et) 2005-02-15
NO20003219L (no) 2000-08-22
IL136823A (en) 2005-08-31
HUP0200618A3 (en) 2003-04-28
MA26577A1 (fr) 2004-12-20
BR9814389A (pt) 2000-10-10
EP1043977A1 (de) 2000-10-18
PL341565A1 (en) 2001-04-23
PT1043977E (pt) 2004-03-31
CN1284868A (zh) 2001-02-21
EE200000395A (et) 2002-02-15
TWI240637B (en) 2005-10-01
AU759311B2 (en) 2003-04-10
EP1043977B1 (de) 2003-10-22
NO20003219D0 (no) 2000-06-21
CA2315927A1 (en) 1999-07-01

Similar Documents

Publication Publication Date Title
EG23875A (en) Oral pharmaceutical pulsed release dosage form
IL136827A0 (en) Oral pharmaceutical extended release dosage form
IL117041A0 (en) Oral pharmaceutical dosage form
GB9613470D0 (en) Small solid oral dosage form
ZA987551B (en) Solid pharmaceutical dosage forms
AU7375598A (en) Stable oral pharmaceutical dosage forms
AU3977099A (en) Controlled release oral dosage form
HUP0203204A3 (en) Oral dosage forms
HUP0201936A3 (en) Multi-component pharmaceutical dosage form
HUP9903407A3 (en) Oral pharmaceutical preparation containing ibandronat
AP9801173A0 (en) Rapidly releasing and taste-making pharmaceutical dosage
IL138192A0 (en) Controlled release oral dosage forms
EP1207852A4 (de) Orale darreichung mit gesteuerter freisetzung zur oralen verabreichung
IL136028A0 (en) Novel oral dosage form for carvedilol
SI1043977T1 (en) Oral pharmaceutical pulsed release dosage form
SI1043976T1 (sl) Oralna farmacevtska dozirna oblika s podaljsanim sproscanjem
HUP0101012A3 (en) Pharmaceutical composition for oral administration
IL120172A0 (en) Pharmaceutical dosage form
GB9712357D0 (en) Pharmaceutical dosage form
IL123341A0 (en) Pharmaceutical dosage form
HK1047232A1 (zh) 口服劑型
GB9925069D0 (en) Oral dosage form
IL117184A0 (en) Pharmaceutical dosage form
GB9711046D0 (en) Oral pharmaceutical compositions
IL128582A0 (en) Pharmaceutical dosage form